<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Trial Design - Comprehensive Guide</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: #f5f7fa;
            padding: 40px 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            padding: 40px;
            border-radius: 15px;
            box-shadow: 0 5px 30px rgba(0,0,0,0.1);
        }
        
        .title {
            font-size: 36px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 15px;
            text-align: center;
        }
        
        .subtitle {
            font-size: 18px;
            color: #666;
            text-align: center;
            margin-bottom: 40px;
        }
        
        .content-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 25px;
            margin-bottom: 30px;
        }
        
        .trial-card {
            background: #f8f9fb;
            border: 3px solid #1E64C8;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
            position: relative;
            overflow: hidden;
        }
        
        .trial-card:hover {
            background: #e8f2ff;
            transform: translateY(-5px);
            box-shadow: 0 8px 25px rgba(30, 100, 200, 0.3);
        }
        
        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 15px;
        }
        
        .card-icon {
            width: 45px;
            height: 45px;
            background: linear-gradient(135deg, #1E64C8 0%, #5088d4 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
            box-shadow: 0 4px 12px rgba(30, 100, 200, 0.3);
        }
        
        .card-title {
            font-size: 18px;
            font-weight: 700;
            color: #1E64C8;
            flex: 1;
        }
        
        .card-content {
            font-size: 15px;
            color: #333;
            line-height: 1.6;
            margin-bottom: 12px;
        }
        
        .visual-diagram {
            margin-top: 12px;
            padding-top: 12px;
            border-top: 2px dashed #1E64C8;
        }
        
        .diagram-svg {
            width: 100%;
            height: 70px;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, #1E64C8 0%, #5088d4 100%);
            color: white;
            padding: 20px 30px;
            border-radius: 12px;
            text-align: center;
            font-size: 18px;
            font-weight: 600;
            line-height: 1.6;
            margin-bottom: 50px;
        }
        
        .detailed-section {
            margin-top: 50px;
            padding-top: 40px;
            border-top: 3px solid #1E64C8;
        }
        
        .section-title {
            font-size: 32px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 40px;
            text-align: center;
        }
        
        .trial-detail {
            margin-bottom: 60px;
            background: #f8f9fb;
            padding: 35px;
            border-radius: 15px;
            border-left: 6px solid #1E64C8;
        }
        
        .trial-detail-header {
            display: flex;
            align-items: center;
            gap: 15px;
            margin-bottom: 25px;
            padding-bottom: 20px;
            border-bottom: 2px solid #1E64C8;
        }
        
        .detail-icon {
            width: 60px;
            height: 60px;
            background: linear-gradient(135deg, #1E64C8 0%, #5088d4 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 30px;
            box-shadow: 0 4px 15px rgba(30, 100, 200, 0.3);
        }
        
        .detail-title {
            font-size: 26px;
            font-weight: 700;
            color: #1E64C8;
        }
        
        .detail-content {
            display: grid;
            gap: 25px;
        }
        
        .subsection {
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.05);
        }
        
        .subsection-title {
            font-size: 18px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 12px;
            display: flex;
            align-items: center;
            gap: 8px;
        }
        
        .subsection-content {
            font-size: 15px;
            color: #333;
            line-height: 1.8;
        }
        
        .subsection-content ul {
            margin-left: 20px;
            margin-top: 10px;
        }
        
        .subsection-content li {
            margin-bottom: 8px;
        }
        
        .example-box {
            background: #e8f2ff;
            padding: 20px;
            border-radius: 10px;
            border-left: 4px solid #1E64C8;
            margin-top: 15px;
        }
        
        .example-title {
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 10px;
            font-size: 16px;
        }
        
        .example-content {
            font-size: 14px;
            color: #333;
            line-height: 1.7;
        }
        
        .key-features {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 15px;
        }
        
        .feature-item {
            background: #e8f2ff;
            padding: 15px;
            border-radius: 8px;
            font-size: 14px;
            color: #333;
            display: flex;
            align-items: start;
            gap: 10px;
        }
        
        .feature-icon {
            color: #1E64C8;
            font-weight: 700;
            font-size: 16px;
        }
        
        .large-diagram {
            width: 100%;
            max-width: 800px;
            margin: 25px auto;
            display: block;
        }
        
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 20px;
            background: white;
        }
        
        .comparison-table th {
            background: #1E64C8;
            color: white;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }
        
        .comparison-table td {
            padding: 12px;
            border: 1px solid #ddd;
            font-size: 14px;
        }
        
        .comparison-table tr:nth-child(even) {
            background: #f8f9fb;
        }
        
        .advantage {
            color: #4CAF50;
            font-weight: 600;
        }
        
        .disadvantage {
            color: #f44336;
            font-weight: 600;
        }
        
        @media print {
            body {
                background: white;
            }
            .trial-card:hover {
                transform: none;
                box-shadow: none;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="title">Clinical Trial Design</div>
        <div class="subtitle">Master Protocols in Precision Medicine</div>
        
        <div class="content-grid">
            <div class="trial-card">
                <div class="card-header">
                    <div class="card-icon">üß∫</div>
                    <div class="card-title">Basket Trials</div>
                </div>
                <div class="card-content">
                    Multiple tumor types with same molecular alteration
                </div>
                <div class="visual-diagram">
                    <svg class="diagram-svg" viewBox="0 0 300 70">
                        <circle cx="150" cy="35" r="18" fill="#1E64C8"/>
                        <text x="150" y="40" fill="white" font-size="11" font-weight="bold" text-anchor="middle">BRAF</text>
                        
                        <circle fill="none" stroke="#1E64C8" stroke-width="2" cx="80" cy="15" r="12"/>
                        <text x="80" y="19" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">Lung</text>
                        <line x1="92" y1="20" x2="135" y2="30" stroke="#1E64C8" stroke-width="2"/>
                        
                        <circle fill="none" stroke="#1E64C8" stroke-width="2" cx="80" cy="55" r="12"/>
                        <text x="80" y="59" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">Colon</text>
                        <line x1="92" y1="50" x2="135" y2="40" stroke="#1E64C8" stroke-width="2"/>
                        
                        <circle fill="none" stroke="#1E64C8" stroke-width="2" cx="220" cy="15" r="12"/>
                        <text x="220" y="19" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">Melanoma</text>
                        <line x1="208" y1="20" x2="165" y2="30" stroke="#1E64C8" stroke-width="2"/>
                        
                        <circle fill="none" stroke="#1E64C8" stroke-width="2" cx="220" cy="55" r="12"/>
                        <text x="220" y="59" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">Thyroid</text>
                        <line x1="208" y1="50" x2="165" y2="40" stroke="#1E64C8" stroke-width="2"/>
                    </svg>
                </div>
            </div>
            
            <div class="trial-card">
                <div class="card-header">
                    <div class="card-icon">‚òÇÔ∏è</div>
                    <div class="card-title">Umbrella Trials</div>
                </div>
                <div class="card-content">
                    Single disease with multiple biomarker-driven arms
                </div>
                <div class="visual-diagram">
                    <svg class="diagram-svg" viewBox="0 0 300 70">
                        <rect x="130" y="5" width="40" height="20" rx="4" fill="#1E64C8"/>
                        <text x="150" y="18" fill="white" font-size="10" font-weight="bold" text-anchor="middle">NSCLC</text>
                        
                        <line x1="150" y1="25" x2="70" y2="50" stroke="#1E64C8" stroke-width="2"/>
                        <line x1="150" y1="25" x2="150" y2="50" stroke="#1E64C8" stroke-width="2"/>
                        <line x1="150" y1="25" x2="230" y2="50" stroke="#1E64C8" stroke-width="2"/>
                        
                        <rect fill="white" opacity="0.9" x="50" y="50" width="40" height="16" rx="3"/>
                        <text x="70" y="61" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">EGFR+</text>
                        
                        <rect fill="white" opacity="0.9" x="130" y="50" width="40" height="16" rx="3"/>
                        <text x="150" y="61" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">ALK+</text>
                        
                        <rect fill="white" opacity="0.9" x="210" y="50" width="40" height="16" rx="3"/>
                        <text x="230" y="61" fill="#1E64C8" font-size="9" font-weight="bold" text-anchor="middle">KRAS+</text>
                    </svg>
                </div>
            </div>
            
            <div class="trial-card">
                <div class="card-header">
                    <div class="card-icon">üîÑ</div>
                    <div class="card-title">Platform Trials</div>
                </div>
                <div class="card-content">
                    Perpetual trials adding/dropping arms dynamically
                </div>
                <div class="visual-diagram">
                    <svg class="diagram-svg" viewBox="0 0 300 70">
                        <rect x="100" y="10" width="100" height="50" rx="6" fill="#1E64C8"/>
                        <text x="150" y="30" fill="white" font-size="12" font-weight="bold" text-anchor="middle">Platform</text>
                        <text x="150" y="45" fill="white" font-size="9" text-anchor="middle">Master Protocol</text>
                        
                        <rect fill="white" opacity="0.9" x="20" y="20" width="55" height="12" rx="2"/>
                        <text x="47.5" y="29" fill="#1E64C8" font-size="8" font-weight="bold" text-anchor="middle">Arm 1</text>
                        <line x1="75" y1="26" x2="100" y2="30" stroke="white" stroke-width="2" stroke-dasharray="3,2"/>
                        
                        <rect fill="white" opacity="0.9" x="20" y="38" width="55" height="12" rx="2"/>
                        <text x="47.5" y="47" fill="#1E64C8" font-size="8" font-weight="bold" text-anchor="middle">Arm 2</text>
                        <line x1="75" y1="44" x2="100" y2="40" stroke="white" stroke-width="2" stroke-dasharray="3,2"/>
                        
                        <rect fill="white" opacity="0.9" x="225" y="20" width="55" height="12" rx="2"/>
                        <text x="252.5" y="29" fill="#1E64C8" font-size="8" font-weight="bold" text-anchor="middle">New Arm</text>
                        <line x1="200" y1="30" x2="225" y2="26" stroke="white" stroke-width="2" stroke-dasharray="3,2"/>
                        <text x="270" y="15" fill="#4CAF50" font-size="10" font-weight="bold">+</text>
                        
                        <rect fill="white" opacity="0.3" x="225" y="38" width="55" height="12" rx="2"/>
                        <text x="252.5" y="47" fill="#666" font-size="8" font-weight="bold" text-anchor="middle">Dropped</text>
                        <line x1="200" y1="40" x2="225" y2="44" stroke="white" stroke-width="2" stroke-dasharray="3,2" opacity="0.3"/>
                        <text x="270" y="52" fill="#f44336" font-size="10" font-weight="bold">-</text>
                    </svg>
                </div>
            </div>
            
            <div class="trial-card">
                <div class="card-header">
                    <div class="card-icon">üìä</div>
                    <div class="card-title">Biomarker-stratified</div>
                </div>
                <div class="card-content">
                    Randomization based on biomarker status
                </div>
                <div class="visual-diagram">
                    <svg class="diagram-svg" viewBox="0 0 300 70">
                        <rect x="10" y="25" width="70" height="20" rx="4" fill="#1E64C8"/>
                        <text x="45" y="38" fill="white" font-size="10" font-weight="bold" text-anchor="middle">Patients</text>
                        
                        <circle cx="130" cy="35" r="18" fill="#5088d4"/>
                        <text x="130" y="40" fill="white" font-size="9" font-weight="bold" text-anchor="middle">Test</text>
                        <line x1="80" y1="35" x2="112" y2="35" stroke="#1E64C8" stroke-width="2"/>
                        
                        <line x1="148" y1="35" x2="170" y2="20" stroke="#1E64C8" stroke-width="2"/>
                        <rect fill="white" opacity="0.9" x="170" y="10" width="50" height="16" rx="2"/>
                        <text x="195" y="21" fill="#4CAF50" font-size="9" font-weight="bold" text-anchor="middle">Positive</text>
                        <text x="245" y="21" fill="#1E64C8" font-size="8" text-anchor="start">‚Üí Drug A</text>
                        
                        <line x1="148" y1="35" x2="170" y2="50" stroke="#1E64C8" stroke-width="2"/>
                        <rect fill="white" opacity="0.9" x="170" y="44" width="50" height="16" rx="2"/>
                        <text x="195" y="55" fill="#f44336" font-size="9" font-weight="bold" text-anchor="middle">Negative</text>
                        <text x="245" y="55" fill="#1E64C8" font-size="8" text-anchor="start">‚Üí Drug B</text>
                    </svg>
                </div>
            </div>
        </div>
        
        <div class="highlight-box">
            Master Protocols: Efficient frameworks for precision oncology trials
        </div>

        <!-- DETAILED SECTIONS -->
        <div class="detailed-section">
            <div class="section-title">Detailed Trial Designs & Examples</div>

            <!-- BASKET TRIALS -->
            <div class="trial-detail">
                <div class="trial-detail-header">
                    <div class="detail-icon">üß∫</div>
                    <div class="detail-title">Basket Trials</div>
                </div>
                
                <div class="detail-content">
                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üìã</span>
                            Overview
                        </div>
                        <div class="subsection-content">
                            Basket trials enroll patients with different tumor types that share a common molecular alteration or biomarker. The treatment is targeted to the specific genetic mutation rather than the organ of origin. This design reflects the precision medicine paradigm where drugs target specific molecular pathways regardless of where the cancer originated.
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üéØ</span>
                            Key Characteristics
                        </div>
                        <div class="key-features">
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Single drug targeting specific biomarker across multiple cancer types</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Patients grouped into "baskets" by tumor type</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Separate efficacy analysis for each tumor type</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Allows borrowing of information across baskets</span>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üî¨</span>
                            Clinical Examples
                        </div>
                        <div class="subsection-content">
                            <div class="example-box">
                                <div class="example-title">NCI-MATCH Trial (Molecular Analysis for Therapy Choice)</div>
                                <div class="example-content">
                                    One of the largest basket trials testing multiple targeted therapies across various cancer types based on specific genetic mutations. Patients are assigned to treatment arms based on their tumor's molecular profile, regardless of cancer origin. Over 35 different treatment arms targeting specific mutations like PIK3CA, BRAF, and EGFR.
                                </div>
                            </div>
                            
                            <div class="example-box">
                                <div class="example-title">VE-BASKET Study</div>
                                <div class="example-content">
                                    Evaluated vemurafenib (BRAF V600 inhibitor) in multiple BRAF V600 mutation-positive cancers including non-small cell lung cancer, cholangiocarcinoma, ovarian cancer, and colorectal cancer. Demonstrated variable response rates across different tumor types, highlighting tissue-specific factors in treatment efficacy.
                                </div>
                            </div>

                            <div class="example-box">
                                <div class="example-title">KEYNOTE-158</div>
                                <div class="example-content">
                                    Basket trial of pembrolizumab (anti-PD-1) in patients with advanced cancers with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). Led to the first tissue-agnostic FDA approval based on a biomarker rather than tumor location.
                                </div>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">‚öñÔ∏è</span>
                            Advantages & Challenges
                        </div>
                        <div class="subsection-content">
                            <table class="comparison-table">
                                <tr>
                                    <th>Advantages</th>
                                    <th>Challenges</th>
                                </tr>
                                <tr>
                                    <td class="advantage">Accelerates drug development for rare mutations</td>
                                    <td class="disadvantage">Variable response rates across tumor types</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Efficient patient enrollment for rare biomarkers</td>
                                    <td class="disadvantage">Complex statistical analysis and interpretation</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Cost-effective compared to multiple separate trials</td>
                                    <td class="disadvantage">Requires extensive molecular screening infrastructure</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Enables tissue-agnostic drug approvals</td>
                                    <td class="disadvantage">May need large sample sizes per basket</td>
                                </tr>
                            </table>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üí°</span>
                            Design Considerations
                        </div>
                        <div class="subsection-content">
                            <ul>
                                <li><strong>Statistical approach:</strong> Bayesian hierarchical models often used to borrow information across baskets while accounting for heterogeneity</li>
                                <li><strong>Sample size:</strong> Must balance adequate power within each basket with overall feasibility</li>
                                <li><strong>Interim analyses:</strong> Allows early stopping of non-responsive baskets while continuing promising ones</li>
                                <li><strong>Biomarker testing:</strong> Centralized, standardized testing critical for trial integrity</li>
                                <li><strong>Regulatory pathway:</strong> May support accelerated approval or tissue-agnostic indications</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- UMBRELLA TRIALS -->
            <div class="trial-detail">
                <div class="trial-detail-header">
                    <div class="detail-icon">‚òÇÔ∏è</div>
                    <div class="detail-title">Umbrella Trials</div>
                </div>
                
                <div class="detail-content">
                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üìã</span>
                            Overview
                        </div>
                        <div class="subsection-content">
                            Umbrella trials focus on a single disease or cancer type but test multiple targeted therapies matched to different molecular subtypes. Patients are assigned to specific treatment arms based on their tumor's biomarker profile. This design recognizes that a single cancer type comprises multiple molecular subtypes requiring different therapeutic approaches.
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üéØ</span>
                            Key Characteristics
                        </div>
                        <div class="key-features">
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Single disease with molecular subtyping</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Multiple treatment arms for different biomarkers</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Centralized screening and assignment</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Shared control arm possible</span>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üî¨</span>
                            Clinical Examples
                        </div>
                        <div class="subsection-content">
                            <div class="example-box">
                                <div class="example-title">LUNG-MAP (Lung Cancer Master Protocol)</div>
                                <div class="example-content">
                                    A precision medicine trial in squamous cell lung cancer. Patients undergo biomarker testing and are assigned to sub-studies based on their molecular profile. Multiple drug arms test targeted therapies or immunotherapies. Includes biomarker-negative patients who go to immunotherapy arms. Allows addition of new arms as therapies become available.
                                </div>
                            </div>
                            
                            <div class="example-box">
                                <div class="example-title">I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response)</div>
                                <div class="example-content">
                                    Adaptive platform trial in early-stage breast cancer testing multiple neoadjuvant therapies. Uses biomarker signatures to assign patients to treatment arms. Employs Bayesian adaptive randomization to increase assignment to more effective treatments. Has graduated multiple therapies to Phase III trials based on predictive biomarker signatures.
                                </div>
                            </div>

                            <div class="example-box">
                                <div class="example-title">ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial)</div>
                                <div class="example-content">
                                    Umbrella trial in early-stage non-small cell lung cancer. Screens patients for EGFR mutations and ALK rearrangements. Those with targetable mutations are enrolled in sub-studies testing targeted therapies in the adjuvant setting. Includes biomarker-negative patients in observational cohort.
                                </div>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">‚öñÔ∏è</span>
                            Advantages & Challenges
                        </div>
                        <div class="subsection-content">
                            <table class="comparison-table">
                                <tr>
                                    <th>Advantages</th>
                                    <th>Challenges</th>
                                </tr>
                                <tr>
                                    <td class="advantage">Tests multiple therapies simultaneously within one disease</td>
                                    <td class="disadvantage">High screening failure rate if biomarkers are rare</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Efficient use of single-disease patient population</td>
                                    <td class="disadvantage">Complex logistics and coordination</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Shared infrastructure and control arms reduce costs</td>
                                    <td class="disadvantage">Some molecular subgroups may be too small</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Facilitates biomarker-driven treatment selection</td>
                                    <td class="disadvantage">Requires rapid turnaround on biomarker testing</td>
                                </tr>
                            </table>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üí°</span>
                            Design Considerations
                        </div>
                        <div class="subsection-content">
                            <ul>
                                <li><strong>Biomarker strategy:</strong> Must define clear, actionable biomarkers with validated assays</li>
                                <li><strong>Screening logistics:</strong> Efficient pathway from diagnosis to molecular testing to treatment assignment</li>
                                <li><strong>Control strategy:</strong> May use shared control, standard of care, or biomarker-negative cohort</li>
                                <li><strong>Adaptive features:</strong> Can add new arms as therapies emerge or drop ineffective arms</li>
                                <li><strong>Patient experience:</strong> Streamlined process from one screening to multiple possible treatments</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- PLATFORM TRIALS -->
            <div class="trial-detail">
                <div class="trial-detail-header">
                    <div class="detail-icon">üîÑ</div>
                    <div class="detail-title">Platform Trials</div>
                </div>
                
                <div class="detail-content">
                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üìã</span>
                            Overview
                        </div>
                        <div class="subsection-content">
                            Platform trials are perpetual, adaptive trials with a master protocol allowing new treatment arms to be added and ineffective arms to be dropped over time. They maintain a common infrastructure and control group while evaluating multiple therapies simultaneously. This design maximizes efficiency and accelerates the evaluation of new treatments.
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üéØ</span>
                            Key Characteristics
                        </div>
                        <div class="key-features">
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Continuously operating trial infrastructure</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Dynamic addition and removal of treatment arms</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Shared control group across all arms</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Adaptive randomization based on performance</span>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üî¨</span>
                            Clinical Examples
                        </div>
                        <div class="subsection-content">
                            <div class="example-box">
                                <div class="example-title">RECOVERY Trial (Randomised Evaluation of COVID-19 Therapy)</div>
                                <div class="example-content">
                                    Landmark platform trial for COVID-19 treatments. Started with multiple arms including hydroxychloroquine, lopinavir-ritonavir, dexamethasone, and azithromycin. Rapidly identified dexamethasone as effective and hydroxychloroquine as ineffective. Added new arms (tocilizumab, convalescent plasma) as evidence emerged. Enrolled over 40,000 patients across UK hospitals with streamlined enrollment.
                                </div>
                            </div>
                            
                            <div class="example-box">
                                <div class="example-title">STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer)</div>
                                <div class="example-content">
                                    Multi-arm, multi-stage platform trial in prostate cancer running since 2005. Has evaluated numerous treatment combinations including docetaxel, zoledronic acid, abiraterone, enzalutamide, and radiotherapy. Uses shared control arm and adaptive design. Has led to multiple changes in standard of care based on arm results. Continues to add new treatment arms as therapies become available.
                                </div>
                            </div>

                            <div class="example-box">
                                <div class="example-title">GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment)</div>
                                <div class="example-content">
                                    Platform trial for newly diagnosed and recurrent glioblastoma. Tests multiple experimental therapies simultaneously using Bayesian adaptive design. Arms can graduate to Phase III or be dropped for futility based on interim analyses. Allows seamless addition of promising new agents. Uses biomarker stratification within platform framework.
                                </div>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">‚öñÔ∏è</span>
                            Advantages & Challenges
                        </div>
                        <div class="subsection-content">
                            <table class="comparison-table">
                                <tr>
                                    <th>Advantages</th>
                                    <th>Challenges</th>
                                </tr>
                                <tr>
                                    <td class="advantage">Maximally efficient use of control patients</td>
                                    <td class="disadvantage">Complex infrastructure requires significant resources</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Accelerated drug evaluation pipeline</td>
                                    <td class="disadvantage">Statistical adjustments needed for multiple comparisons</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Flexible to add promising new therapies quickly</td>
                                    <td class="disadvantage">Coordination across multiple pharmaceutical sponsors</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Can answer multiple questions simultaneously</td>
                                    <td class="disadvantage">Requires sophisticated data management and monitoring</td>
                                </tr>
                            </table>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üí°</span>
                            Design Considerations
                        </div>
                        <div class="subsection-content">
                            <ul>
                                <li><strong>Master protocol:</strong> Comprehensive framework covering all operational and statistical aspects</li>
                                <li><strong>Governance structure:</strong> Independent oversight committee to review interim results and make decisions</li>
                                <li><strong>Entry/exit criteria:</strong> Pre-specified rules for adding new arms and stopping ineffective ones</li>
                                <li><strong>Adaptive randomization:</strong> Can weight randomization toward better-performing arms</li>
                                <li><strong>Control strategy:</strong> May use concurrent controls, allow controls to be time-limited, or use historical controls</li>
                                <li><strong>Statistical framework:</strong> Typically Bayesian to allow continuous learning and adaptation</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- BIOMARKER-STRATIFIED TRIALS -->
            <div class="trial-detail">
                <div class="trial-detail-header">
                    <div class="detail-icon">üìä</div>
                    <div class="detail-title">Biomarker-Stratified Trials</div>
                </div>
                
                <div class="detail-content">
                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üìã</span>
                            Overview
                        </div>
                        <div class="subsection-content">
                            Biomarker-stratified trials randomize patients based on their biomarker status, allowing assessment of treatment efficacy in biomarker-defined subgroups. This design can test whether a treatment works differently in biomarker-positive versus biomarker-negative patients, or compare different treatments within biomarker-defined strata. Essential for developing companion diagnostics and precision therapies.
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üéØ</span>
                            Key Characteristics
                        </div>
                        <div class="key-features">
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Prospective biomarker testing before randomization</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Separate randomization within each biomarker stratum</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Can test for biomarker-treatment interaction</span>
                            </div>
                            <div class="feature-item">
                                <span class="feature-icon">‚úì</span>
                                <span>Supports companion diagnostic development</span>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üî¨</span>
                            Design Variations
                        </div>
                        <div class="subsection-content">
                            <div class="example-box">
                                <div class="example-title">Enrichment Design</div>
                                <div class="example-content">
                                    Enrolls only biomarker-positive patients to maximize signal detection. Example: EGFR-mutant lung cancer trials with EGFR inhibitors. Most efficient for demonstrating efficacy when treatment expected to work only in biomarker-positive population.
                                </div>
                            </div>
                            
                            <div class="example-box">
                                <div class="example-title">Biomarker-Stratified Design</div>
                                <div class="example-content">
                                    Enrolls all patients but stratifies randomization by biomarker status. Allows testing treatment effect in both positive and negative strata. Can formally test for interaction. Example: Testing anti-PD-L1 therapy stratified by PD-L1 expression level.
                                </div>
                            </div>

                            <div class="example-box">
                                <div class="example-title">Strategy Design</div>
                                <div class="example-content">
                                    Compares biomarker-guided treatment selection versus standard treatment for all. One arm gets tested and treated based on biomarker, other arm gets standard approach. Tests whether biomarker strategy improves outcomes. Example: TAILORx trial in breast cancer comparing gene expression-guided versus standard chemotherapy decisions.
                                </div>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üî¨</span>
                            Clinical Examples
                        </div>
                        <div class="subsection-content">
                            <div class="example-box">
                                <div class="example-title">TAILORx (Trial Assigning Individualized Options for Treatment)</div>
                                <div class="example-content">
                                    Stratified trial in early-stage breast cancer using 21-gene recurrence score. Patients with mid-range scores randomized to chemotherapy plus endocrine therapy versus endocrine therapy alone. Demonstrated that most patients with intermediate scores can safely avoid chemotherapy. Changed practice guidelines worldwide.
                                </div>
                            </div>

                            <div class="example-box">
                                <div class="example-title">BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)</div>
                                <div class="example-content">
                                    Used multiple biomarkers to assign treatments in refractory non-small cell lung cancer. Adaptive randomization increased assignment to treatments performing well in specific biomarker groups. Demonstrated feasibility of real-time biomarker-adaptive design.
                                </div>
                            </div>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">‚öñÔ∏è</span>
                            Advantages & Challenges
                        </div>
                        <div class="subsection-content">
                            <table class="comparison-table">
                                <tr>
                                    <th>Advantages</th>
                                    <th>Challenges</th>
                                </tr>
                                <tr>
                                    <td class="advantage">Increased power in biomarker-positive subgroup</td>
                                    <td class="disadvantage">Larger total sample size needed</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Can identify predictive biomarkers definitively</td>
                                    <td class="disadvantage">Requires validated, accessible biomarker test</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Supports companion diagnostic approval</td>
                                    <td class="disadvantage">Screen failure rate if biomarker is rare</td>
                                </tr>
                                <tr>
                                    <td class="advantage">Avoids exposing biomarker-negative patients to ineffective therapy</td>
                                    <td class="disadvantage">Logistical complexity of pre-randomization testing</td>
                                </tr>
                            </table>
                        </div>
                    </div>

                    <div class="subsection">
                        <div class="subsection-title">
                            <span class="feature-icon">üí°</span>
                            Design Considerations
                        </div>
                        <div class="subsection-content">
                            <ul>
                                <li><strong>Biomarker validation:</strong> Must use analytically and clinically validated assay</li>
                                <li><strong>Sample size calculation:</strong> Consider prevalence of biomarker and expected treatment effects in each stratum</li>
                                <li><strong>Testing turnaround time:</strong> Must be rapid enough to not delay treatment significantly</li>
                                <li><strong>Statistical analysis plan:</strong> Pre-specify how biomarker-treatment interaction will be tested</li>
                                <li><strong>Regulatory considerations:</strong> Plan for companion diagnostic co-development if applicable</li>
                                <li><strong>Equity considerations:</strong> Ensure biomarker testing accessible to diverse patient populations</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- COMPARISON TABLE -->
            <div class="trial-detail">
                <div class="trial-detail-header">
                    <div class="detail-icon">üìà</div>
                    <div class="detail-title">Comparative Summary</div>
                </div>
                
                <div class="detail-content">
                    <div class="subsection">
                        <div class="subsection-content">
                            <table class="comparison-table">
                                <tr>
                                    <th>Design Type</th>
                                    <th>Primary Goal</th>
                                    <th>Best Used When</th>
                                    <th>Key Advantage</th>
                                </tr>
                                <tr>
                                    <td><strong>Basket</strong></td>
                                    <td>Test one drug across multiple tumor types with same biomarker</td>
                                    <td>Rare actionable mutation across cancers</td>
                                    <td>Enables tissue-agnostic approvals</td>
                                </tr>
                                <tr>
                                    <td><strong>Umbrella</strong></td>
                                    <td>Test multiple drugs in one disease with different biomarkers</td>
                                    <td>Well-characterized molecular subtypes exist</td>
                                    <td>Comprehensive coverage of one disease</td>
                                </tr>
                                <tr>
                                    <td><strong>Platform</strong></td>
                                    <td>Continuously evaluate multiple treatments</td>
                                    <td>Many experimental therapies to evaluate</td>
                                    <td>Maximally efficient, perpetual infrastructure</td>
                                </tr>
                                <tr>
                                    <td><strong>Biomarker-Stratified</strong></td>
                                    <td>Define predictive biomarker and treatment effect</td>
                                    <td>Need to validate biomarker-treatment relationship</td>
                                    <td>Strongest evidence for companion diagnostic</td>
                                </tr>
                            </table>
                        </div>
                    </div>
                </div>
            </div>

        </div>
    </div>
</body>
</html>